Literature DB >> 26343130

The Past, Present and Future Subclassification of Patients with Acute Myeloid Leukemia.

Rakel B Forthun1, Carina Hinrichs, Tara H Dowling, Øystein Bruserud, Frode Selheim.   

Abstract

Acute myeloid leukemia (AML) is characterized as a heterogeneous disease where the patients are sub grouped according to several classification systems and mutational analyses. Diagnosis of AML is based on identification of the specific myeloid cell initiating the disease, quantification of immature blasts in bone marrow and peripheral blood, as well as detection of mutations and translocations. The heterogeneity of AML is caused by a block in differentiation that may occur in any of the different myeloid cell populations. These undifferentiated cells also harbor an increased proliferation potential that leads to accumulation of immature leukemic cells. The current development of more sensitive and less labor intensive analysis methods has led classification of patients from being a system based on morphology of the leukemic cells to being more sophisticated, detecting translocations and small mutations found in the whole leukemic clone or in a minor subclone. This review aims to describe the most common classification systems of AML, including frequently occurring translocations, mutations and epigenetic alterations, as well as describe traditional and novel methods for diagnosis and analysis of these patients.

Entities:  

Mesh:

Year:  2016        PMID: 26343130     DOI: 10.2174/1389201016666150907113653

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  3 in total

1.  MicroRNA-183 promotes cell proliferation via regulating programmed cell death 6 in pediatric acute myeloid leukemia.

Authors:  Xiang Wang; Dongjian Zuo; Yufang Yuan; Xiaochun Yang; Ze Hong; Rongrong Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2016-10-13       Impact factor: 4.553

2.  A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model.

Authors:  Alexia Mopin; Virginie Driss; Carine Brinster
Journal:  J Vis Exp       Date:  2016-10-14       Impact factor: 1.355

3.  Cytoplasmic proliferating cell nuclear antigen connects glycolysis and cell survival in acute myeloid leukemia.

Authors:  Delphine Ohayon; Alessia De Chiara; Nicolas Chapuis; Céline Candalh; Julie Mocek; Jean-Antoine Ribeil; Lamya Haddaoui; Norbert Ifrah; Olivier Hermine; Frédéric Bouillaud; Philippe Frachet; Didier Bouscary; Véronique Witko-Sarsat
Journal:  Sci Rep       Date:  2016-10-19       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.